Cargando…

Receptor tyrosine kinases: role in cancer progression

Detalles Bibliográficos
Autores principales:	Sangwan, V., Park, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Multimed Inc. 2006
Materias:	Updates and Development in Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3394603/ https://www.ncbi.nlm.nih.gov/pubmed/22792017

Ejemplares similares

Protein tyrosine phosphatases: new markers and targets in oncology?
por: Hardy, S., et al.
Publicado: (2008)

The role of dna hypermethylation and demethylation in cancer and cancer therapy
por: Szyf, M.
Publicado: (2008)

Role of vaccine therapy in cancer: biology and practice
por: Schlom, J., et al.
Publicado: (2007)

Hepatocyte growth factor and the hepatocyte growth factor receptor signalling complex as targets in cancer therapies
por: Jiang, W.G.
Publicado: (2007)

Promising agents for chemoprevention of skin cancer
por: Stratton, S.P., et al.
Publicado: (2006)

Radiolabelled monoclonal antibodies in the treatment of metastatic cancer
por: Goldenberg, D.M.
Publicado: (2007)

Are matrix metalloproteinases relevant therapeutic targets for prostate cancer bone metastasis?
por: Bonfil, R.D., et al.
Publicado: (2008)

Cancer and thrombosis: recent advances
por: Solymoss, S.
Publicado: (2008)

Anal cancer and human papillomaviruses in heterosexual men
por: Nyitray, A.
Publicado: (2008)

Targeting transforming growth factor β to enhance cancer immunotherapy
por: Hahn, T., et al.
Publicado: (2006)

Cancer symptom control trials: how may we advance this field?
por: MacDonald, N.
Publicado: (2007)

Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics
por: Williams, P.D., et al.
Publicado: (2009)

Comparing the results of bisphosphonate use in clinical trials with actual practice: a case of apples and oranges?
por: Gainford, M.C., et al.
Publicado: (2006)

Electrochemotherapy of tumours
por: Sersa, G., et al.
Publicado: (2009)

Retinoids, vitamin D, invasion, and metastasis
por: Tokar, E.J., et al.
Publicado: (2006)

The antitumour activities of statins
por: Takahashi, H.K., et al.
Publicado: (2007)

Exosomes in tumour immunity
por: Clayton, A., et al.
Publicado: (2009)

Radiation oncology: Times of practice change
por: Freeman, C.R., et al.
Publicado: (2007)

Radiofrequency ablation and cryoablation of renal tumours
por: Kwan, K.G., et al.
Publicado: (2007)

Recent advances in the tumour biology of the GPI-anchored carcinoembryonic antigen family members CEACAM5 and CEACAM6
por: Chan, C.H.F., et al.
Publicado: (2007)

Proteomic quantification of receptor tyrosine kinases involved in the development and progression of colorectal cancer liver metastasis
por: Vasilogianni, Areti-Maria, et al.
Publicado: (2023)

Microbes and colorectal cancer: is there a relationship?
por: Uronis, J.M., et al.
Publicado: (2009)

Profiling Receptor Tyrosine Kinase Fusions in Chinese Breast Cancers
por: Tao, Zhonghua, et al.
Publicado: (2021)

Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer
por: Kraeber–Bodéré, F., et al.
Publicado: (2009)

PMON30 Low-dose Infigratinib, an Oral Selective Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor, Demonstrates Activity in a Preclinical Model of Hypochondroplasia
por: Dambkowski, Carl, et al.
Publicado: (2022)

Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
por: Tian, Zhichao, et al.
Publicado: (2020)

The Receptor Tyrosine Kinase AXL in Cancer Progression
por: Rankin, Erinn B., et al.
Publicado: (2016)

Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target
por: Pidkovka, Nataliya, et al.
Publicado: (2023)

Monitoring clinical progression with mitochondrial disease biomarkers
por: Steele, Hannah E, et al.
Publicado: (2017)

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and Lung Cancer: History, Epidemiology, and Market Outlook
por: Miles, Brittany, et al.
Publicado: (2021)

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma
por: Breitenecker, Kristina, et al.
Publicado: (2023)

Syndecans and Their Synstatins: Targeting an Organizer of Receptor Tyrosine Kinase Signaling at the Cell-Matrix Interface
por: Rapraeger, Alan C.
Publicado: (2021)

Protocol update and baseline characteristics for the TRIal to slow the Progression of Diabetes (TRIPOD) randomized controlled trial
por: Bairavi, Joann, et al.
Publicado: (2023)

Tyrosine kinases in nodal peripheral T-cell lymphomas
por: Piccaluga, Pier Paolo, et al.
Publicado: (2023)

Protein Tyrosine Kinase 7 Regulates EGFR/Akt Signaling Pathway and Correlates With Malignant Progression in Triple-Negative Breast Cancer
por: Cui, Nai-Peng, et al.
Publicado: (2021)

Tyrosine Kinase ROR1 as a Target for Anti-Cancer Therapies
por: Zhao, Yuming, et al.
Publicado: (2021)

Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma
por: Fleuren, Emmy D. G., et al.
Publicado: (2023)

A kaleidoscope of photosynthetic antenna proteins and their emerging roles
por: Arshad, Rameez, et al.
Publicado: (2022)

Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer
por: Barnes, Tristan A., et al.
Publicado: (2017)

Role of the Brk tyrosine kinase in breast cancer progression
por: Harvey, AJ, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_rh6bhqbmd5jrhg5g5lc11ig5p2